NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, Forecast & News

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) posted its quarterly earnings results on Thursday, October, 31st. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.09. The biotechnology company earned $6.40 million during the quarter, compared to analysts' expectations of $5.24 million. Momenta Pharmaceuticals had a negative net margin of 361.66% and a negative return on equity of 59.82%. The company's quarterly revenue was down 57.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.65) EPS. View Momenta Pharmaceuticals' Earnings History.

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Momenta Pharmaceuticals.

8 brokerages have issued 1 year price targets for Momenta Pharmaceuticals' stock. Their forecasts range from $14.15 to $50.00. On average, they expect Momenta Pharmaceuticals' share price to reach $33.64 in the next year. This suggests a possible upside of 9.2% from the stock's current price. View Analyst Price Targets for Momenta Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Momenta Pharmaceuticals.

News stories about MNTA stock have been trending very negative recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Momenta Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Momenta Pharmaceuticals.

Some companies that are related to Momenta Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), Amicus Therapeutics (FOLD), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), ImmunoGen (IMGN), Novavax (NVAX), Halozyme Therapeutics (HALO), Portola Pharmaceuticals (PTLA), Mylan (MYL) and Omeros (OMER).

Momenta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (17.53%), State Street Corp (3.87%), Perceptive Advisors LLC (2.86%), Farallon Capital Management LLC (2.78%), Palo Alto Investors LP (1.70%) and Point72 Asset Management L.P. (1.64%). Company insiders that own Momenta Pharmaceuticals stock include Alejandra Carvajal, Anthony M Manning, Bruce Downey, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Ian Fier, Jo Ann Beltramello, Jose-Carlos Gutierrez-Ramos, Michelle Robertson, Santiago Arroyo and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.

MNTA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Citigroup Inc., Peregrine Capital Management LLC, State of New Jersey Common Pension Fund D, Palo Alto Investors LP, Perceptive Advisors LLC and UBS Group AG. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Alejandra Carvajal, Anthony M Manning, Bruce Downey, Craig A Wheeler, Elizabeth Stoner, Ian Fier, Jo Ann Beltramello, Jose-Carlos Gutierrez-Ramos, Michelle Robertson, Santiago Arroyo and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.

MNTA stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, FMR LLC, RA Capital Management L.P., Jennison Associates LLC, UBS Asset Management Americas Inc., AXA, Driehaus Capital Management LLC and State Street Corp. View Insider Buying and Selling for Momenta Pharmaceuticals.

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MNTA stock can currently be purchased for approximately $30.80.

Momenta Pharmaceuticals has a market capitalization of $3.05 billion and generates $75.59 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Momenta Pharmaceuticals employs 131 workers across the globe.View Additional Information About Momenta Pharmaceuticals.

The official website for Momenta Pharmaceuticals is http://www.momentapharma.com/.

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]